Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY25 results · Jan–Mar 2025
Ajanta Pharma reported revenue from operations of ₹1,170.41 crore (up 11.0% from Q4 FY24) and net profit of ₹225.26 crore (up 11.1% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,170.41 | 1,054.08 | +11.0% | 1,146.13 | +2.1% |
| Other income | 18.11 | 35.50 | −49.0% | 30.44 | −40.5% |
| Total income | 1,188.52 | 1,089.58 | +9.1% | 1,176.57 | +1.0% |
| Profit before tax | 269.41 | 278.04 | −3.1% | 307.39 | −12.4% |
| Net profit for the period | 225.26 | 202.72 | +11.1% | 232.88 | −3.3% |
| EPS, basic (₹) | 18.00 | 16.10 | +11.8% | 18.60 | −3.2% |
| Net margin (%) | 19.2 | 19.2 | 20.3 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,013.94 | 926.07 | +9.5% | 1,101.92 | −8.0% |
| Other income | 17.93 | 33.68 | −46.8% | 33.23 | −46.0% |
| Total income | 1,031.87 | 959.75 | +7.5% | 1,135.15 | −9.1% |
| Profit before tax | 228.15 | 225.94 | +1.0% | 332.15 | −31.3% |
| Net profit for the period | 193.43 | 162.69 | +18.9% | 252.45 | −23.4% |
| EPS, basic (₹) | 15.46 | 12.92 | +19.7% | 20.16 | −23.3% |
| Net margin (%) | 19.1 | 17.6 | 22.9 |
Consolidated
- Filed with BSE
- 30 Apr 2025, 17:39 IST
- Board meeting
- 30 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Apr 2025, 17:39 IST
- Board meeting
- 30 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE